Omnicell, Inc.

DB:OC9 Stock Report

Market Cap: €2.0b

Omnicell Valuation

Is OC9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OC9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OC9 (€43.4) is trading below our estimate of fair value (€55.67)

Significantly Below Fair Value: OC9 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OC9?

Key metric: As OC9 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OC9. This is calculated by dividing OC9's market cap by their current revenue.
What is OC9's PS Ratio?
PS Ratio2x
SalesUS$1.06b
Market CapUS$2.12b

Price to Sales Ratio vs Peers

How does OC9's PS Ratio compare to its peers?

The above table shows the PS ratio for OC9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.7x
DRW3 Drägerwerk KGaA
0.2x4.2%€796.1m
AFX Carl Zeiss Meditec
2.4x7.9%€5.0b
EUZ Eckert & Ziegler
3x6.3%€831.3m
SBS Stratec
1.3x7.7%€321.5m
OC9 Omnicell
2x6.0%€2.1b

Price-To-Sales vs Peers: OC9 is expensive based on its Price-To-Sales Ratio (2x) compared to the peer average (1.7x).

Price to Sales Ratio vs Industry

How does OC9's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$827.50m
PHH2 Paul Hartmann
0.3xn/aUS$791.49m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
OC9 2.0xIndustry Avg. 3.5xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: OC9 is good value based on its Price-To-Sales Ratio (2x) compared to the European Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is OC9's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OC9 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2x
Fair PS Ratio1.3x

Price-To-Sales vs Fair Ratio: OC9 is expensive based on its Price-To-Sales Ratio (2x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OC9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€43.40
€53.90
+24.2%
13.8%€65.83€41.98n/a8
Nov ’25€44.40
€52.01
+17.1%
17.4%€63.44€34.02n/a7
Oct ’25€38.60
€38.80
+0.5%
20.8%€54.50€26.81n/a7
Sep ’25€40.00
€38.80
-3.0%
20.8%€54.50€26.81n/a7
Aug ’25€26.80
€32.96
+23.0%
21.2%€41.70€24.09n/a7
Jul ’25€25.20
€30.79
+22.2%
19.0%€37.16€24.15n/a7
Jun ’25€30.00
€30.79
+2.6%
19.0%€37.16€24.15n/a7
May ’25€25.20
€30.40
+20.6%
19.0%€36.54€23.75n/a7
Apr ’25€26.80
€30.40
+13.4%
19.0%€36.54€23.75n/a7
Mar ’25€24.00
€31.12
+29.7%
18.0%€37.08€24.10n/a7
Feb ’25€29.60
€34.52
+16.6%
20.2%€46.12€25.82n/a7
Jan ’25€35.00
€36.68
+4.8%
22.5%€46.63€26.11n/a6
Dec ’24€30.60
€36.68
+19.9%
22.5%€46.63€26.11n/a6
Nov ’24€33.40
€58.53
+75.3%
17.7%€70.81€36.82€44.407
Oct ’24€42.20
€65.76
+55.8%
19.7%€83.27€36.90€38.608
Sep ’24€52.00
€64.48
+24.0%
13.4%€80.42€51.18€40.009
Aug ’24€56.00
€63.49
+13.4%
14.1%€79.07€50.32€26.809
Jul ’24€67.50
€64.45
-4.5%
11.8%€80.39€53.90€25.209
Jun ’24€67.50
€62.93
-6.8%
8.2%€69.08€54.34€30.009
May ’24€54.50
€60.49
+11.0%
8.9%€68.62€52.15€25.209
Apr ’24€53.50
€61.38
+14.7%
9.5%€70.34€53.46€26.809
Mar ’24€53.50
€61.38
+14.7%
9.5%€70.34€53.46€24.009
Feb ’24€51.50
€60.62
+17.7%
12.1%€69.02€49.70€29.608
Jan ’24€45.00
€61.88
+37.5%
13.3%€70.20€50.54€35.009
Dec ’23€48.80
€72.87
+49.3%
37.7%€147.24€52.31€30.609
Nov ’23€77.00
€150.55
+95.5%
13.9%€190.90€118.67€33.4010

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.0%

1Y

-38.8%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.1%

1Y

16.0%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%